AI assistant
Revenio Group Oyj — Director's Dealing 2023
Feb 16, 2023
3236_dirs_2023-02-16_b9d70d64-c0e2-4ce0-b3a5-6fac898f5c14.pdf
Director's Dealing
Open in viewerOpens in your device viewer
Revenio Group Corporation: Managers' Transactions –John Floyd
Revenio Group Corporation, Managers' transactions, February 16, 2023 at 4.00 p.m. (EET)
Revenio Group Oyj - Managers' Transactions –John Floyd
Person subject to the notification requirement Name: John Floyd Position: Other senior manager
Issuer: Revenio Group Oyj LEI: 743700I27E0FWSXLKK04 Notification type: INITIAL NOTIFICATION Reference number: 25540/7/6
Transaction date: 2023-02-15 Outside a trading venue Instrument type: SHARE ISIN: FI0009010912 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details (1): Volume: 1496 Unit price: 0 EUR Aggregated transactions (1): Volume 1496 Volume weighted average price: 0 EUR
For further information, please contact
CFO Robin Pulkkinen, tel. +358 50 505 9932 [email protected] www.revenio.fi
Distribution Nasdaq Helsinki FIN-FSA Key media www.revenio.fi/en
Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical
software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.
In 2022, the Group's net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
Attachments
Revenio Group Corporation: Managers' Transactions –John Floyd